WallStSmart

Merck & Company Inc (MRK)vsOraSure Technologies Inc (OSUR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 58094% more annual revenue ($65.77B vs $113.02M). MRK leads profitability with a 13.6% profit margin vs -66.4%. MRK appears more attractively valued with a PEG of 5.36. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

OSUR

Hold

40

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 4.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for OSUR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

OSUR4 strengths · Avg: 9.3/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
29.6%8/10

Earnings expanding 29.6% YoY

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

OSUR4 concerns · Avg: 2.5/10
Market CapQuality
$291.92M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
6.192/10

Expensive relative to growth rate

Return on EquityProfitability
-21.2%2/10

ROE of -21.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OSUR

The strongest argument for OSUR centers on Price/Book, Altman Z-Score, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : OSUR

The primary concerns for OSUR are Market Cap, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

MRK profiles as a value stock while OSUR is a turnaround play — different risk/reward profiles.

OSUR carries more volatility with a beta of 1.01 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 40/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

OraSure Technologies Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.

Want to dig deeper into these stocks?